napabucasin + ibrutinib

Combination of **napabucasin** (a small molecule inhibitor of cancer cell stemness, designed to block multiple stemness pathways including STAT3, thereby inhibiting cancer stem cell growth and resulting in antineoplastic effects) and **ibrutinib** (an orally active small molecule inhibitor of Bruton’s tyrosine kinase [BTK], primarily used for B-cell malignancies). No clinical trials were found for this exact combination. Each drug is orally administered, and both have been investigated and/or approved (ibrutinib) for various cancer indications. Napabucasin’s primary developer is Boston Biomedical, while ibrutinib was originally developed by Pharmacyclics and Janssen (Johnson & Johnson/AbbVie). The combination does not appear to have an established, branded combination product; rather, both drugs are sometimes studied/proposed for advanced cancers as part of exploratory or off-label protocols.

Brand names

IMBRUVICA (for ibrutinib)

Other names

2-Acetylfuro-1,4-naphthoquinone (napabucasin)2-acetylnaphtho[2,3-b]furan-4,9-dione (napabucasin)2-acetylbenzo[f][1]benzofuran-4,9-dione (napabucasin)BBI-608 (napabucasin)2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione (napabucasin)2-Acetylfuranonaphthoquinone (napabucasin)Z1HHM49K7O (napabucasin)BBI 608 (napabucasin)IMBRUVICA (ibrutinib, brand name by Janssen)